Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study

ConclusionsThe saroglitazar treatment significantly improved postprandial TGs in people with diabetic dyslipidemia.Trial registrationClinical Trial Registry of India; trial Registration No.: CTRI/2015/06/005845 and Date of registration: June 02, 2015.

Source: Acta Diabetologica - February 5, 2020 Category: Endocrinology Source Type: research